Showing results (341-350 of 355) with videos related to
Sort By:
Pageof 36
Nature Genetics|August 4, 2015
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancerFolefac Aminkeng, Amit P Bhavsar, Henk Visscher, et al.Pediatric Nephrology (Berlin, Germany)|October 19, 2022
Acute kidney injury during cisplatin therapy and associations with kidney outcomes 2 to 6 months post-cisplatin in children: a multi-centre, prospective observational studyKelly R McMahon, Asaf Lebel, Shahrad Rod Rassekh, et al.Genes|May 15, 2019
Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer PatientsZulfan Zazuli, Leila S Otten, Britt I Drögemöller, et al.British Journal of Clinical Pharmacology|May 6, 2026
Metabolomic investigation of cisplatin-induced acute kidney injury in paediatric cancer patientsYong Jin Lim, Amy Thachil, Kelly McMahon, et al.The Pharmacogenomics Journal|May 28, 2014
Pharmacogenomic diversity in Singaporean populations and EuropeansL R Brunham, S L Chan, R Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2011
Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in childrenHenk Visscher, Colin J D Ross, S Rod Rassekh, et al.JAMA Oncology|April 28, 2017
Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular CancerBritt I Drögemöller, Jose G Monzon, Amit P Bhavsar, et al.Liver International : Official Journal of the International Association for the Study of the Liver|February 2, 2022
Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis CCatrina M Loucks, Jennifer J Lin, Jessica N Trueman, et al.Nature Genetics|July 18, 2018
Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosisKaarina Kowalec, Galen E B Wright, Britt I Drögemöller, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 12, 2022
A pharmacogenomic investigation of the cardiac safety profile of ondansetron in children and pregnant womenBritt I Drögemöller, Galen E B Wright, Jessica Trueman, et al.Pageof 36